By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



8 rue de la Croix Jarry

Paris    75013  France
Phone: 33-0-1-81-69-16-00 Fax: n/a


Key Statistics

Ownership: Public

Web Site: Cellectis
Symbol: CLLS



Company News
Cellectis (CLLS) To Explore Possible Initial Public Offering Of Calyxt 4/13/2017 6:16:08 AM
Five Additional Leading Physicians To Join Cellectis (CLLS) Clinical Advisory Board 3/8/2017 7:07:34 AM
Cellectis (CLLS) Reports 4th Quarter And Full Year 2016 Financial Results 3/7/2017 6:37:01 AM
No Looking Back: Cellectis (CLLS) Preps for Cutting-Edge 'Off-the-Shelf' CAR-T Trial 2/7/2017 6:44:43 AM
FDA Grants Cellectis (ALCLS) IND Approval To Proceed With The Clinical Development Of UCART123, The First Gene Edited Off-The-Shelf CAR T-Cell Product Candidate Developed In The U.S. 2/7/2017 6:35:04 AM
Scientists Highlight the Hopes and Fears of Cellectis (ALCLS)' CAR-T 1/26/2017 6:02:54 AM
Cellectis (ALCLS) Release: Four Prominent Physicians To Join Clinical Advisory Board 1/24/2017 8:28:00 AM
Cellectis (ALCLS) Release: Biopharma Studies Safety in New CAR Architecture Controlling CAR T-Cell Functions 1/23/2017 7:26:07 AM
Cellectis (ALCLS) Submits IND Application For UCART123, An Allogeneic Gene Edited CAR T-Cell Product Candidate, In AML And BPDCN 1/4/2017 10:00:50 AM
Cellectis (ALCLS) Announces Recombinant DNA Advisory Committee’s (RAC) Unanimous Approval Of UCART123 Phase 1 Study Protocols In AML And BPDCN 12/16/2016 11:38:43 AM